Immunostimulants for preventing respiratory tract infection in children

Evidence-Based Child Health

Volumn 7, Issue 2, 2012, Pages 629-717

  Del Rio Navarro, Blanca Estela ^a   Espinosa Rosales, Francisco J ^b   Flenady, Vicki ^c   Sienra Monge, Juan J L ^a  

^a HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^b InstitutoNacional de Pediatría National Institute of Pediatrics   (Mexico)

^c MATER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867925027     PISSN: None     EISSN: 15576272     Source Type: Journal    
DOI: 10.1002/ebch.1833     Document Type: Review

References (81)

1. Ahrens J. Multicentre double-blind clinical trial with broncho-vaxom in children. Therapiewoche 1984;34: 3469-75.
2. Andrianova IV, Sobenin IA, Sereda EV, Borodina LI, Studenikin MI. Effect of long-acting garlic tablets "allicor" on the incidence of acute respiratory viral infections in children. Terapevticheskii Arkhiv 2003;75(3):53-6.
3. Arroyave CM. Klebsiella pneumoniae glycoproteins as coadjuvants in the prevention of recurrent respiratory infections in children 1 to 6 years of age [Glicoproteínas de Klebsiella pneumoniae como coadyuvantes en la prevención de infecciones recurrentes respiratorias en niños de 1 a 6 años de edad]. Revista Alergia México 1999;46(3):66-71.
4. Burgio GR, Marseglia GL, Severi F, De Benedetti F, Masarone M, Ottolenghi A, et al. Immunoactivation by pidotimod in children with recurrent respiratory infections. Arzneimittelforschung 1994;44(SUPPL 12A): 152-9.
5. Caramia G, Clemente E, Solli R, Mei V, Cera R, Carnelli V, et al. Efficacy and safety of pidotimod in the treatment of recurrent respiratory infections in children. Arzneimittelforschung 1994;44(Suppl 12A):1480-4.
6. Careddu P. Role of immunoactivation with pidotimod in recurrent respiratory infections in childhood. Arzneimittelforschung 1994;44(Suppl 12A):1506-11.
7. Careddu P, Biolchini A, Alfano S, Zavattini G. Pidotimod in the prophylaxis of recurrent acute tonsillitis in childhood. Advances in Oto-Rhino-Laryngology 1992;47:328-31.
8. Careddu P, Alfano S, Zavattini G. Pidotimod in the prophylaxis of recurrent acute tonsillitis in childhood. Advances in Therapy 1992;9(3):174-83.
9. Careddu P, Mei V, Venturoli V, Corsini A. Pidotimod in the treatment of recurrent respiratory infections in paediatric patients. Arzneimittelforschung 1994;44(Suppl 12A):1485-9.
10. Chen AH, Chen RC, Zhang CQ, Chen D, Huang S, Lin Y, et al. Efficacy of sublingual polyvalent bacterial vaccine (Lantigen B) in children with recurrent respiratory infection: a randomized double-blind controlled clinical trial. Zhonghua Er Ke Za Zhi [Chinese Journal of Pediatrics] 2004;42(6):463-4.
11. Clerici-Schoeller M, Careddu P, Sandri MT, Cazzola P. Recurrent respiratory infections in children: prevention of acute episodes by oral administration of thymomodulin. Current Therapeutic Research, Clinical and Experimental 1988;44(4):503-9.
12. Cohen HA, Varsano I, Kahan E, Sarrell EM, Uziel Y. Effectiveness of an herbal preparation containing echinacea, propolis, and vitamin C in preventing respiratory tract infections in children: a randomized, double-blind, placebo-controlled, multicenter study. Archives of Pediatrics & Adolescent Medicine 2004;158(3):217-21.
13. Aymard M, Chomel JJ, Allard JP, Thouvenot D, Honegger D, Floret D, et al. Epidemiology of viral infections and evaluation of the potential benefit of OM-85 BV on the virologic status of children attending day-care centers. Respiration 1994;61(Suppl 1):24-31.
14. Collet JP, Ducruet T, Kramer MS, Haggerty J, Floret D, Chomel JJ, et al. Stimulation of nonspecific immunity to reduce the risk of recurrent infections in children attending day-care centers. The Epicreche Research Group. Pediatric Infectious Disease Journal 1993;12(8):648-52.
15. De Loore F, Heck E, Van Eygen M, Casneuf J. Levamisole (R 12564) in the prevention of recurrent upper respiratory tract infections in children: a double-blind, placebocontrolled study. Current Medical Research and Opinion 1979;6(2):142-7.
16. Del Río Navarro BE, Luis Sienra Monge JJ, Berber A, Torres Alcantara S, Avila Castañón L, Gómez Barreto D. Use of OM-85 BV in children suffering from recurrent respiratory tract infections and subnormal IgG subclass levels. Allergologia et Immunopathologia 2003;31:7-13.
17. Dils F. A placebo controlled, double-blind evaluation of levamisole in the reduction of the frequency, duration and severity of attacks in children suffering from recurrent upper respiratory tract infections. Journal of International Medical Research 1979;7(4):302-4.
18. Fiocchi A, Borella E, Riva E, Arensi D, Travaglini P, Cazzola P, et al. A double-blind clinical trial for the evaluation of the therapeutical effectiveness of a calf thymus derivative (thymomodulin) in children with recurrent respiratory infections. Thymus 1986;8(6):331-9.
19. Fiocchi A, Zuccotti G, Rottoli A, Grasso U, Pogliani L, Vimercati E, et al. Treatment with immucytal in recidivant respiratory infection in the pediatric age [Trattamento con immucytal nele infezioni respiratorie recidivanti in eta pediatrica]. Rivista di Pediatria Preventiva e Sociale 1988;38 (4):213-9.
20. Fiocchi A, Arancio R, Cinquepalmi P, Sala M, Zuccotti GV, Riva E, et al. Recurrent respiratory infections in childhood: experience with a bacterial extract plus bacterial ribosomes (immucytal). Journal of International Medical Research 1990;18(1):50-60.
21. Fiocchi A, Vignati B, Cinquepalmi P, Machado E, Peano L, Pulejo R, et al. Treatment using immucytal in children with recurrent respiratory infections: an Italian multicenter experience [Terapia con immucytal di bambini affetti da infezioni respiratorie recidivanti: esperienza italina policentrica]. La Pediatria Medica e Chirurgica 1989;11(3): 285-92.
22. Fukuda Y, Jordão-Neves BM, da-Cunha J, Mangabeira Albernaz PL. Assessment of efficacy and safety of thymomodulin (Leucogen®) in the prevention of recurrent otitis media and recurrent tonsillitis [Estudo clínico-imunológico da eficácia de timomodulina (Leucogen®) na otite média aguda recorrente e na amigdalite de repetição]. Pediatria Moderna 1999;XXV (10):828-34. [www.moerirajr.com.br/pediatriamoderna/ped1099/pedleuco.htm]
23. Bellanti J, Olivieri D, Serrano E. Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 2003;17:355-67.
24. Boyle P, Bellantu JA, Robertson C. Meta-analysis of published clinical trials of a ribosomal vaccine (Ribomunyl R) in prevention of respiratory infections. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 2000;14:389-408.
25. Garabedian EN, Dubreuil C, Triglia JC. Effectiveness and tolerance of Ribomunyl tablets in preventing middle ear infections in children affected by S.O.M. International Congress on Prevention of Infection, Nice, France. 1990.
26. Giovannini M, Fiocchi A, Sala M, Fontana P, Fiori L, Silano M, et al. Immucytal(R) in the prevention and treatment of recurrent upper respiratory tract infections in children: a randomized, placebo-controlled, double-blind study. International Journal of Immunotherapy 2000;16(3-4): 67-75.
27. Gutiérrez-Tarango MD, Berber A. Safety and efficacy of two courses of OM-85 BV in the prevention of respiratory tract Infections in children during 12 months. Chest 2001; 119(6):1742-8.
28. Gomez Barreto D, De la Torre C, Alvarez A, Faure A, Berber A. Safety and efficacy of OM-85-BV plus amoxicillin/ clavulanate in the treatment of subacute sinusitis and the prevention of recurrent infections in children [Seguridad y eficacia de OM-85-BV más amoxicilina/clavulanato en el tratamiento de la sinusitis subaguda y prevención de infecciones recurrentes en niños]. Allergologia et Immunopathologia 1998;26(1):17-22.
29. Bellanti J, Olivieri D, Serrano E. Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 2003;17:355-67.
30. Boyle P, Bellantu JA, Robertson C. Meta-analysis of published clinical trials of a ribosomal vaccine (Ribomunyl R) in prevention of respiratory infections. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 2000;14:389-408.
31. Haguernauer JP. Prevention of the ENT repeating infectious episodes by D53 tablets in children of less than 5 years [Prévention des épisodes infectieux récidivants de la sphére ORL par D53 comimés chez lénfant de moins de 5 ans]. Immunologie Medicale 1987;18:36-9.
32. Bellanti J, Olivieri D, Serrano E. Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 2003;17:355-67.
33. Hüls P, Welbers P, Lindemann H. Immunotherapy of children with the help of a multibacterial ribosomal preparation [Immuntherapie bei kindern mit hilfe eines multibakteriellen ribosomenpräparates]. Der Kinderartz 1995;26(8):1018-24.
34. Iuldashev AK, Slepushkin AN, Khodzhaeva MA, Schastnyi EI, Kamilov FK. Prophylactic efficacy of reaferon in viral hepatitis A and acute respiratory infections in children. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 1988;5:65-9.
35. Jara-Perez JV, Berber A. Primary prevention of acute respiratory tract infections in children using a bacterial immunostimulant: a double-masked, placebo-controlled clinical trial. Clinical Therapeutics 2000;22(6):748-59.
36. Karam-Bechara J, Rodríguez-Suárez R, Fuare-Fontela A, Posada-Maldonado EE, Rivera-Gutiérrez SM, Sánchez-Díaz R. Thymomodulin in the prevention of recurrent infectious episodes of chronic bronchitis in pediatric patients. Double blind trial [Timomodulina en la prevención de los episodios infecciosos recurrentes de la bronquitis crónica en pacientes pediátricos. Estudio doble ciego]. Investigación Médica Internacional 1995;22(43):43-51.
37. Bellanti J, Olivieri D, Serrano E. Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 2003;17:355-67.
38. Boyle P, Bellantu JA, Robertson C. Meta-analysis of published clinical trials of a ribosomal vaccine (Ribomunyl R) in prevention of respiratory infections. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 2000;14:389-408.
39. Lacomme Y, Narcy P. Prevention of the repeating episodes of ENT superinfection by ribosomal immunotherapy in the child. Clinical results of a multicenter study [Prévention par immunothérapie ribosomale des épisodes de superinfection récidivantes de la sphére ORL chez l'enfant. Résultats cliniques d'une étude multicentrique]. Immunologie Medicale 1985;11:73-5.
40. Litzman J, Lokaj J, Krejci M, Pesak S, Morgan G. Isoprinosine does not protect against frequent respiratory tract infections in childhood. European Journal of Pediatrics 1999;158(1):32-7.
41. Longo F, Lepore L, Agosti E, Panizon F. Evaluation of the effectiveness of thymomodulin in children with recurrent respiratory infections. La Pediatria Medica e Chirurgica 1988;10(6):603-7.
42. Losa GA, Maestroni GJ. Clinical and immunobiological action of an orally administered bacterial extract. Schweizerische Medizinische Wochenschrift 1984;114(25): 930-2.
43. Maestroni GJ, Losa GA. Clinical and immunobiological effects of an orally administered bacterial extract. International Journal of Immunopharmacology 1984;6(2): 111-7.
44. Martin du Pan RE, Martin du Pan RC. Clinical study concerning the prevention of infections of the upper respiratory tract of preschool children. Schweizerische Rundschau fur Medizin Praxis 1982;71(36):1385-9.
45. Mora R, Barbieri M, Passali GC, Sovatzis A, Mora F, Cordone MP. A preventive measure for otitis media in children with upper respiratory tract infections. International Journal of Pediatric Otorhinolaryngology 2002; 63(2):111-8.
46. Mora R, Dellepiane M, Crippa B, Salami A. Ribosomal therapy in the prophylaxis of recurrent pharyngotonsillitis in children. International Journal of Pediatric Otorhinolaryngology 2007;71(2):257-61.
47. Mora R, Dellepiane M, Crippa B, Guastini L, Santomauro V, Salami A. Ribosomal therapy in the treatment of recurrent acute adenoiditis. European Archives of Oto-Rhino-Laryngology 2010 (in press (pending)).
48. Motta G, De Campora E, De Vita C, Esposito S, Galletti C, Incutti V, et al. Immunoactivity of pidotimod against episodes of recurrent tonsillitis in childhood. Arzneimittelforschung 1994;44(Suppl 12A):1521-4.
49. Passali D, Calearo C, Conticello S. Pidotimod in the management of recurrent pharyngotonsillar infections in childhood. Arzneimittelforschung 1994;44(12A):1511-6.
50. Passali D, Calearo C, Conticello S, Ferri P, Zavattini G. Recurrent pharingo-tonsillar infections in infants. Treatment with pidotimod [Le infezioni ricorrenti faringo-tonsillari dell'infanzia: tattamento con pidotimod]. Otorinolaringologia Pediatrica 1994;V(3):231-9.
51. Paupe J, Paupe G. Biostim prevention of recurrent respiratory infections in children. A double-blind versus placebo study [Prévention par le biostim des infections respiratoiresá répétition chez l'enfant]. Annales de Pediatrie 1986;33(9):843-5.
52. Paupe J. Immunotherapy with an oral bacterial extract (OM-85 BV) for upper respiratory infections. Respiration 1991;58(3-4):150-4.
53. Paupe J. Value of Imocur in the prevention of recurrent infections in children under six years of age. Results of a multicenter, placebo-controlled trial [Interet d'imocur(r) dans la prevention des infections recidivantes del'enfant de moins de six ans. Resultats d'une etude multicentrique contre placebo]. Annales de Pediatrie 1990;37(7):475-9.
54. Pech A, Zanaret M. Double blind trial of biostim versus placebo in children repeating rhinopharyngities [Etude du biostim double aveugle contre placebo dans les rhinopharyngities récidivantes del'enfant]. Les Cahiers d'ORL 1987;22:217-20.
55. Reinert P, Morales M, Brin S, Fagnani. Evaluation of RU 41740 for the prevention of recurrent nasopharyngeal infections in pediatric patients [Evaluation d'un traitement preventif par RU 41740 (biostim) des infections rhinopharyngees recidivantes de l'enfant]. Annales de Pediatrie 1995;42:454-60.
56. Piquet JJ, Piedro P. Bisotim investigation in the treatment of recurrent ENT infections in children [Intéret du biostim dans le traitement des infections ORL récidivantes de l'enfant]. Les Cahiers d'ORL 1986;21:725-30.
57. Reinert P, Morales M, Brin S, Fagnani. Evaluation of RU 41740 for the prevention of recurrent nasopharyngeal infections in pediatric patients [Evaluation d'un traitement preventif par RU 41740 (biostim) des infections rhinopharyngees recidivantes de l'enfant]. Annales de Pediatrie 1995;42:454-60.
58. Pozzi E, Serra C. Efficacy of Lantigen B in the prevention of bacterial respiratory infections. Monaldi Archives for Chest Disease 2004;61(1):19-27.
59. Bellanti J, Olivieri D, Serrano E. Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 2003;17:355-67.
60. Bellanti J, Olivieri D, Serrano E. Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 2003;17:355-67.
61. Bellanti J, Olivieri D, Serrano E. Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 2003;17:355-67.
62. Bellanti J, Olivieri D, Serrano E. Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 2003;17:355-67.
63. Bellanti J, Olivieri D, Serrano E. Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 2003;17:355-67.
64. Bellanti J, Olivieri D, Serrano E. Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 2003;17:355-67.
65. Renzo M, Giovanni R, Maria PF, Barbara C, Stefano O, Francesco M, et al. Short ribosomal prophylaxis in the prevention of clinical recurrences of chronic otitis media in children. International Journal of Pediatric Otorhinolaryngology 2004;68(1):83-9.
66. Riedl-Seifert RJ, van Aubel A, Kammereit A, Elsasser U. Reduction of the number and severity of respiratory tract infections in children by oral immunostimulation. Advances in Experimental Medicine and Biology 1995;371B:799-802.
67. Rutishauser M, Pitzke P, Grevers G, van Aubel A, Elsasser U, Kammereit A. Use of a polyvalent bacterial lysate in patients with recurrent respiratory tract infections: results of a prospective, placebo-controlled, randomized, doubleblind study. Advances in Therapy 1998;15(6):330-41.
68. Saracho-Weber F, Vázquez-Ramos V, Ayala-Barajas C. Evaluation of glycoprotein of Klebsiella pneumoniae efficacy in recurrent infections [Evaluación de la eficacia de glucoproteínas de Klebsiella pneumoniae en infecciones recurrentes]. Alergia Asma e Inmunología Pediátrica 2001;10 (2):33-9.
69. Schaad UB, Farine JC, Fux T. Prospective placebo-controlled double-blind study using a bacterial lysate in infections of the respiratory tract and ENT region in children [Prospective placebo-kontrollierte Doppelblindstudie mit einem Bakterienlysat bei Infektionen der Atemwege und des ORL-Bereiches im Kindesalter]. Helvetica Paediatrica Acta 1986;41(1-2):7-17.
70. Schaad UB, Mutterlein R, Goffin H, BV-Child Study Group. Immunostimulation with OM-85 in children with recurrent infections of the upper respiratory tract: a doubleblind, placebo-controlled multicenter study. Chest 2002; 122:2042-9.
71. Sramek J, Josifko M, Helcl J, Holoubkova E, Janout V, Kozesnik B, et al. Bacterial lysate (I.R.S. 19) applied intranasally in the prevention of acute respiratory diseases in children: A randomized double-blind study. Journal of Hygiene, Epidemiology, Microbiology, and Immunology 1986; 30(4):377-85.
72. Barret B. Efficacy and safety of echinacea in treating upper respiratory tract infections in children: a randomized controlled trial. Journal of Pediatrics 2004;145(1):135-6.
73. Taylor JA, Weber W, Standish L, Quinn H, Goesling J, McGann M, et al. Efficacy and safety of echinacea in treating upper respiratory tract infections in children: a randomized controlled trial. JAMA 2003;290(21): 2824-30.
74. Weber W, Taylor JA, Stoep AV, Weiss NS, Standish LJ, Calabrese C. Echinacea purpurea for prevention of upper respiratory tract infections in children. Journal of Alternative and Complementary Medicine 2005;11:1021-6.
75. Weber WJ, Taylor JA, Vander Stoep A, Weiss N, Standish LJ, Calabrese C. The effect of echinacea purpurea treatment on prevention of upper respiratory tract infections in children. Journal of Investigative Medicine 2004;52(Suppl 2):392.
76. Van Eygen M, Znamensky PY, Heck E, Raymaekers I. Levamisole in prevention of recurrent upper-respiratorytract infections in children. Lancet 1976;1(7956):382-5.
77. Van Eygen M, Dils F, Gillerot J, Verschueren E. A doubleblind pediatric evaluation of levamisole in the prevention of recurrent upper respiratory tract infections. European Journal of Pediatrics 1979;131(3):147-53.
78. Bellanti J, Olivieri D, Serrano E. Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 2003;17:355-67.
79. Vautel JM, Cauquil J, Perruchet AM, Thomas AM. Prevention of recurrent ear, nose, and throat infections in young children with Ribomunyl, double-blind, placebocontrolled study. Current Therapeutic Research, Clinical and Experimental 1993;53(6):722-9.
80. Wahl RA, Aldous MB, Worden KA, Grant KL. Echinacea purpurea and osteopathic manipulative treatment in children with recurrent otitis media: a randomized controlled trial. BMC Complementary and Alternative Medicine 2008;8(56):1-9.
81. Zagar S, Lofler-Badzek D. Broncho-vaxom in children with rhinosinusitis: a double-blind clinical trial. Journal for Oto-Rhino-Laryngology and its Related Specialties 1988;50(6): 397-404.